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Abstract
Background: Catheter-related bloodstream infection (CRBSI) results in significant attributable morbidity and mortality. In
this randomized, double-blind, placebo-controlled trial, we studied the efficacy and safety of a daily ethanol lock for the
prevention of CRBSI in patients with a tunnelled central venous catheter (CVC).
Methodology: From 2005 through 2008, each lumen of the CVC of adult hematology patients was locked for 15 minutes
per day with either 70%-ethanol or placebo, where after the lock solution was flushed through. As a primary endpoint, the
incidence rates of endoluminal CRBSI were compared.
Principal Findings: The intent-to-treat analysis was based on 376 patients, accounting for 448 CVCs and 27,745 catheter
days. For ethanol locks, the incidence of endoluminal CRBSI per 1000 CVC-days was 0.70 (95%-CI, 0.4–1.3), compared to 1.19
(95% confidence interval, 0.7–1.9) for placebo (incidence rate-ratio, 0.59; 95% confidence interval, 0.27–1.30; P = .19). For
endoluminal CRBSI according to the strictest definition (positive hub culture and identical bacterial strain in blood), a 3.6-
fold, non-significant, reduction was observed for patients receiving ethanol (2 of 226 versus 7 of 222; P = .103). No life-
threatening adverse events were observed. More patients receiving ethanol discontinued lock-therapy (11 of 226 versus 1 of
222; P = .006) or continued with decreased lock-frequency (10 of 226 versus 0 of 222; P = .002), due to non-severe adverse
events.
Conclusions: In this study, the reduction in the incidence of endoluminal CRBSI using preventive ethanol locks was non-
significant, although the low incidence of endoluminal CRBSI precludes definite conclusions. Therefore, the lack of statistical
significance may partially reflect a lack of power. Significantly more patients treated with ethanol locks discontinued their
prophylactic treatment due to adverse effects, which were non-severe but reasonably ethanol related. Additional studies
should be performed in populations with higher incidence of (endoluminal) CRBSI. Alternative sources of bacteremia, like
exoluminal CRBSI or microbial translocation during chemotherapy-induced mucositis may have been more important in our
patients.
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Introduction
The indwelling central venous catheter (CVC) has become an
essential feature of modern patient management. However, its use
puts patients at risk for various complications, especially catheter-
related bloodstream infection (CRBSI). CRBSI accounts for a
major cause of healthcare-related bacteremia and leads to
prolonged hospital stay and significant attributable costs.[1–4]
Reported attributable mortality varies from 2% up to 25% in
critically ill patients.[2,5] In a meta-analysis, the odds-ratio for
mortality in patients with CRBSI was 1.65 compared to control
patients who were matched for severity of illness.[5]
In contrast to short-term CVCs, CRBSI in patients with
tunnelled or implanted devices is thought to be mainly caused by
endoluminal colonization due to contamination of the catheter
hub.[6,7] Evidence-based recommendations on CRBSI preven-
tion have been published.[8,9] To some extent, endoluminal
CRBSI can be prevented if an antibiotic solution is instilled in the
catheter.[10–12] However, the preventive use of antibiotics should
be avoided if alternative options exist.[13,14] Although there is
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evidence to support the concept, methodologically appropriate
clinical studies on the use of preventive antiseptic solutions are
scarce. For this purpose, ethanol is increasingly considered as a
promising candidate. For CRBSI-treatment, an ethanol-lock has
been demonstrated to be efficacious in several observational
studies.[15–17] More recently, an ethanol-lock has also been
studied for CRBSI-prevention.[18–21] A major advantage of ethanol
would be the broad antimicrobial spectrum without compromising
future antibiotic treatment. Furthermore, it is cheap and
universally available.
In the current randomized, clinical trial, we study the efficacy
and safety of a daily 70%-ethanol lock on the prevention of
endoluminal CRBSI in hematology patients with long-term
tunnelled catheters.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Ethics statement
The institutional review board approved the protocol; written
informed consent was obtained from all patients.
Study design and ethanol lock procedure
The study was performed at the Erasmus Medical Center, a
tertiary referral hospital with 2 locations in Rotterdam, The
Netherlands. Eligible study-participants were all consecutive adult
(age, .17 years) hematology patients with a tunnelled silicone
CVC, inserted in the preceding 72 hours before study-entry. All
catheters used in this study, were silicone devices (HickmanH), that
were placed at the radiology ward after carefully scrubbing the
insertion site with chorhexidine-containing antiseptics, applying
maximum sterile barrier precautions, including the use of a long-
sleeved sterile gown, cap, mask and gloves, together with the use of
sterile sheet drapes.
Excluded were patients with an alcohol-intolerance or concom-
itant treatment with metronidazole. Patients were enrolled from
July 2005 through August 2008. The study was a randomized,
double-blind, placebo-controlled trial (ClinicalTrials.gov Identifi-
er: NCT00122642). Randomization was performed using a
computer-generated list of randomly assigned permuted blocks.
Randomization was catheter-based, which implies that patients
could be randomized more than once if insertion of a new CVC
was needed. Concealment of allocation and provision of blinding
was guaranteed by uninvolved employees of the Department of
Pharmacy, who delivered patient-labelled ampoules containing
either 70%-ethanol or placebo (0.9% NaCl).
During hospitalization, every lumen of the CVC (3 ml) was
locked for 15 minutes per day, following which the solution was
flushed through with 10 ml 0.9% NaCl. During outpatient
settings, the lock was instilled by the nursing staff once weekly
before renewal of the regular heparin solution.
An investigator-blinded safety analysis was performed after
inclusion of 80 patients, as some patients experienced adverse
effects immediately after flushing the lock solution through. This
provisional analysis led to an amendment that allowed these
patients to continue with a modified lock regimen, in which only 1
lumen was locked per day.
Data collection and definitions
Baseline characteristics included age, sex, presence of neutro-
penia (neutrophil count, ,500 cells/ml) at study-entry, underlying
malignancy, site of catheter insertion, and number of catheter
lumens. During follow-up, we recorded catheter dwell time, stay at
the intensive care unit, treatment with total parenteral nutrition
(TPN), and use of glycopeptides, which is the treatment for
presumed/proven beta-lactamase resistant gram-positive microor-
ganisms in our hospital. Safety data were registered for all patients,
including all-cause mortality during the study episode until 30 days
after catheter removal, and the discontinuation of study medica-
tion. Subjective parameters were recorded for a random sample of
25% of patients by means of a questionnaire.
In case of suspected CRBSI, definitions from current guidelines
were followed.[8] In case of documented bacteremia or when a
glycopeptide was started empirically, a culture of the inside of all
catheter hubs was performed. The catheter insertion site was
cultured in case of local inflammation or unexplained bacteremia.
As our intervention would reasonably prevent only endoluminal
CRBSI, effort was made to distinguish this modality. Strictly
endoluminal CRBSI was defined as a positive central or peripheral
blood culture with the same genotypic (for coagulase-negative
staphylococci (CNS)) or phenotypic (for other microorganisms)
strain cultured from the hub, for which directed antimicrobial
therapy was started. For CNS or other skin-colonizers, $2 blood
cultures had to be positive when no peripheral cultures were
available.
In case of bacteremia, we calculated the differential time-to-
positivity (DTTP), which denotes the difference in time-to-
positivity of a peripheral blood culture minus the time-to-positivity
of a central blood culture. DTTP of $2 hours accurately predicts
the catheter to be the source of the episode of bacteremia, which
applies especially to patients with long-term catheters.[22,23]
Therefore, CRBSI with DTTP of $2 hours in the absence of
insertion site or tunnel infection was considered as a separate
entity. When DTTP was not available, CRBSI was diagnosed in
case of a positive peripheral or central blood culture with an
identical microorganism detected on the catheter tip in the
absence of any other infectious source. The latter two entities were
defined as presumed endoluminal CRBSI, because strictly, these
episodes cannot be diagnosed as endoluminal CRBSI with
absolute certainty, although an endoluminal origin is more likely
in the absence of signs of exoluminal infection. Exoluminal CRBSI
was defined as bacteremia with negative hub cultures, but with the
same strain cultured from blood and a clinically infected insertion
site, combined with either DTTP of $2 hours or an identical
microorganism detected on the tip.
Microbiological procedures
Regardless of suspicion of infection, catheter tips were processed
by the semi-quantitative roll plate method.[24] After incubation
for 72 hours, microorganisms were identified and quantified by
standard microbiological methods. Catheter tip colonization was
defined as a positive semi-quantitative tip culture of $15 colony
forming units (cfu)/ml. Blood cultures were processed according to
routine procedures, using the Bactec system (BD; USA).
For genetic typing of isolated CNS strains, we used arbitrarily-
primed PCR, as described in detail elsewhere.[25,26] Strains were
considered identical if all 3 primers showed corresponding DNA-
fingerprints. When the strain was not available for genotyping,
strains were considered phenotypically identical if antibiotic
susceptibility patterns showed at maximum one disconcordant
result.
Outcome
End points were reviewed by 2 blinded investigators (L.S. and
B.J.R.). Patients with strictly endoluminal CRBSI and patients
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with presumed endoluminal CRBSI were considered as the
primary outcome measure. The predefined secondary goals were
to compare overall CRBSI (including exoluminal infection),
overall bacteremia, incidence of positive hub and catheter tip
cultures, all-cause mortality, and treatment with systemic antibi-
otics (glycopeptides versus other compounds) for both groups.
Safety data were also assessed as a secondary outcome.
Statistics
Statistical analyses were performed using SPSS, version 15.0
(Chicago; USA). Tests were two-sided and a P value ,.05 was
considered statistically significant. Analyses were based on catheter
episodes and performed on a modified intent-to-treat (ITT)
population, consisting of all enrolled patients who received at
least 1 dose of study-solution. Follow-up was censored at the
moment a primary endpoint was diagnosed, at catheter removal,
or at death of patients.
Based on a comparable population, CRBSI was assumed to
occur in $20%.[27] We assumed that the majority of CRBSI
would be endoluminal CRBSI. Therefore, a sample size of 219
catheter episodes per group was calculated to detect a hypothe-
sized 50%-reduction of endoluminal CRBSI with 80% power
(a= .05). According to recommendations of the Centers for
Disease Control and Prevention, we also determined CRBSI rates
per 1000 CVC-days.[28] Kaplan-Meyer curves, to describe the
rate of CRBSI for both groups as a function of time, were
constructed and compared with log-rank tests.
The separate contribution of TPN, stay at the intensive care
unit, underlying disease, neutropenia at time of catheter insertion,
catheter insertion site, and number of catheter lumens were
assessed in a Cox regression model. For secondary endpoints,
differences between groups were analyzed with chi-square tests or
Fisher’s exact tests in case of dichotomous variables; differences in
means were compared with student’s t-tests, as appropriate.
Results
A total of 379 patients were enrolled, accounting for 453
catheter episodes. No study solution was administered in 5
catheter episodes, so the modified ITT-analysis was based on data
obtained from 448 episodes (376 patients). Ethanol locks were
administered in 226 catheter episodes. Characteristics of the 2
groups are summarized in Table 1; a flow-diagram of the study
protocol is provided in Figure 1.
Prophylactic effect of 70%-ethanol lock on CRBSI
The differences between the rates of endoluminal CRBSI in
both groups were not statistically significant (Table 2). For ethanol
locks, a total of 14,262 catheter days and 10 episodes of
endoluminal CRBSI were recorded, accounting for a rate of
0.70 CRBSIs per 1000 CVC-days (95% confidence interval, 0.4–
1.3). For placebo, 16 endoluminal CRBSIs during 13,483 catheter
days were observed, with a rate of 1.19 CRBSIs per 1000 CVC-
days (95% confidence interval, 0.7–1.9). The calculated incidence
rate ratio was 0.59 (95% confidence interval, 0.27–1.30), which
implies a non-significant reduction of 41% for patients treated with
ethanol locks (P = .19). In Figure 2, Kaplan-Meyer curves are
presented to describe the rates of CRBSI as a function of catheter
dwell time. No significant difference was observed when these
curves were compared with log-rank tests (P = .22). In patients who
classified for endoluminal CRBSI according to the strictest
definition (positive hub culture with identical bacterial strain in
blood), a 3.6-fold reduction was observed for patients allocated to
ethanol locks (2 of 226 versus 7 of 222; P= .103).
Neither treatment with TPN nor stay at the intensive care unit,
underlying disease, neutropenia at time of catheter placement,
catheter insertion site, or number of catheter lumens contributed
individually to the development of CRBSI (data not shown).
Secondary goals
Results are presented in Table 1 and 2. The mean catheter
dwell time was 63.1 days (range, 2–486 days) for ethanol locks
versus 60.7 days (range, 4–308 days) for placebo (P= .71). The
mean duration of the use of a glycopeptides (6.0 versus 5.0 days)
did not differ between patients randomized to ethanol locks or
placebo (P= .62). Also, the duration of treatment with other classes
of systemic antibiotics did not differ between ethanol locks (mean
duration, 17.4 days), or placebo (mean duration, 16.7 days).
Overall CRBSI was recorded in 21 of 226 patients allocated to
ethanol locks versus 24 of 222 patients treated with placebo
(P= .71). For overall bacteremia, these results were 91 of 226
versus 91 of 222 patients, respectively (P = .95).
Tip cultures were performed on 347 catheters. Rates of
detection of microbial growth were 49 of 171 in patients treated
with ethanol locks and 57 of 176 in patients allocated to placebo
(P= .52). Of all catheter episodes in which bacteremia was
documented (n= 182), CNS was detected as the causative
pathogen in 106 episodes (58%), which was equally distributed
between both groups, as were other causing microbes (Table 3).
Hub cultures were performed in 147 patients, and were positive in
Table 1. Patient characteristics.
Ethanol Placebo
(n =226) (n=222)
Baseline
Age, mean years (range) 51.7 (18–75) 49.8 (18–74)
Male sex 130 (57.5) 125 (56.3)
Neutropeniaa at insertion 44 (19.5) 47 (21.2)
Underlying malignancy
AML-MDS or ALL 140 (61.9) 119 (53.6)
Other 86 (38.1) 103 (46.4)
Type of central venous catheter
Double-lumen 83 (36.7) 99 (44.6)
Triple-lumen 139 (61.5) 122 (55.0)
Missing data 4 (1.8) 1 (0.4)
Insertion place
Internal jugular vene 214 (94.7) 218 (98.2)
Subclavian vene 5 (2.2) 0 (0.0)
Femoral vene 1 (0.4) 1 (0.4)
Missing data 6 (2.7) 1 (0.4)
Follow-up
Catheter dwell time, mean days
(range)
63.1 (2–486) 60.7 (4–308)
Total parenteral nutrition 117 (51.8) 91 (41)
Stay at intensive care unit 18 (8.0) 13 (5.9)
Data represent numbers (%) of patients unless indicated otherwise. AML-MDS,
acute myeloid leukemia-myelodysplastic syndrome; ALL, acute lymphoblastic
leukemia.
aNeutrophil count, ,500 cells/ml.
doi:10.1371/journal.pone.0010840.t001
Ethanol Lock against CRBSI
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10840
8 patients in the ethanol arm versus 11 patients in the placebo arm
(P= .67). However, different strains were obtained from hubs as
compared with blood cultures in 4 patients, (n = 2 for ethanol and
placebo). Therefore, not all patients with positive hub cultures
qualified for endoluminal CRBSI.
Safety and tolerability aspects
Data are presented in Table 4. All-cause mortality in patients
allocated to ethanol locks was 7 of 226, compared with 5 of 222
patients randomized to placebo (P= .77). None of the involved
deaths were diagnosed with CRBSI during the catheter episode.
No differences were observed in the incidence of thrombosis. In
patients allocated to ethanol locks, 1 device had to be removed
because of a rupture of 1 of the 3 catheter lumens, which occurred
while the patient was asleep. No life-threatening adverse events
were observed. One ethanol treated patient had syncope shortly
after flushing through the first lock solution. During subsequent
ethanol lock procedures, no further adverse effects occurred in this
particular patient. Significantly more patients receiving ethanol
locks discontinued lock therapy (P= .006) or continued with a
frequency-adjusted regimen (P = .002), as compared to placebo.
This was due to subjective feelings of discomfort, including facial
redness or flushing, feelings of drowsiness or an alcohol taste after
flushing the lock solution through. No differences in levels of
hepatic enzymes (aspartate-aminotransferase, g-glutamyl trans-
peptidase) and mean corpuscular volume of red blood cells were
observed after 2 weeks of lock therapy when compared to baseline
values (P..5 for all parameters; data not shown).
Discussion
The present randomized clinical trial on the use of a preventive
ethanol lock showed a non-significant 41%-reduction of endolum-
inal CRBSI in patients allocated to ethanol locks for occurrence of
CRBSI as expressed per 1000 CVC-days. Also, the 3.6-fold
reduction as observed in ethanol lock patients who classified for
endoluminal CRBSI according to the strictest definition was not
significant. No differences were observed for catheter dwell time, use
of glycopeptides and other systemic antibiotics, and rates of overall
CRBSI or bacteremia between groups.
Figure 1. Flow-diagram for numerical illustration of the different stages of the study.
doi:10.1371/journal.pone.0010840.g001
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In patients treated with ethanol locks, 1 device had to be
removed due to loss of integrity of the CVC; another person
experienced an episode of syncope after the first lock procedure
but not after subsequent procedures. No other serious adverse
events were observed, which is in agreement with other reported
data.[20] Significantly more patients treated with ethanol locks
discontinued their prophylactic treatment. All reported adverse
effects were non-severe but reasonably ethanol related. In future
studies, this may partially be circumvented by removing the lock
solution instead of flushing it through, as has safely been done in
other recent studies.[21,29]
We took efforts to perform a double-blind, randomized trial.
However, due to the specific ethanol odour that could be sensed
after opening the ampoules by the nursing team, blinding was not
100% in daily practice. Nevertheless, the principal investigators
were not directly involved in patient management and were
therefore completely blinded at all time. Furthermore, the primary
endpoint has no subjective element in its definition, which may
reasonably minimize potential bias.
Currently, several promising observational in vivo data on the
treatment of CRBSI with ethanol locks have been reported.[15–17]
Overall tolerance of ethanol was good in these studies and no
significant adverse effects were observed. Furthermore, several case-
series on the use of preventive ethanol locks have been published. In a
recent case-series, Mouw and colleagues described 10 TPN-
dependent paediatric patients with tunnelled catheters, who were
treated with a 70%-ethanol lock solution between TPN infu-
sions.[19] Infection rates in 5 children of whom data were available
from the period before initiation of lock therapy declined from 11.2
to 2.1 CRBSIs per 1000 CVC-days. In a recent small randomized
trial, Sanders and colleagues observed a reduced incidence of
CRBSI with a 70%-ethanol lock in hematology patients with
tunnelled CVCs.[21] CRBSI occurred in 3 versus 11 patients in the
ethanol and control groups, respectively (odds-ratio, 0.18; 95%
confidence interval, 0.05–0.65). Catheter survival was longer in the
ethanol group (P= .003). Several differences with our study should
be taken into account. First, Sanders et al. used less stringent CRBSI
definitions. With this respect, it is surprising that the large majority
of CRBSIs was caused by gram-negative microorganisms instead of
staphylococci. One wonders whether these episodes of bacteremia
were the consequence of translocation from the gut rather than
CRBSI. The lack of stringent definitions may also partly explain the
high incidence of CRBSI (31 per 1000 CVC-days) in the control
group, which is around 16 times lower in our present study (1.19 per
1000 CVC-days) and another landmark study.[28] Interestingly,
the preliminary data of a randomized trial performed by Crnich and
colleagues, including 359 long-term tunnelled or implanted CVCs,
showed no benefit of the use of a 50%-ethanol lock for CRBSI-
prevention in hospitalized patients.[29]
Ethanol acts bactericidal and fungicidal against a broad range of
bacteria and even yeasts without concerns of resistance develop-
ment.[18] In vitro, it has been demonstrated that a 15%-ethanol
concentration was able to kill most planktonic microorgan-
Figure 2. Kaplan-Meyer survival curves for comparison of the rate of catheter-related bloodstream infections. Data are presented as a
function of catheter dwell time for patients treated with an ethanol lock (n = 226) or placebo.
doi:10.1371/journal.pone.0010840.g002
Table 2. Overview of endpoints and other parameters.
Ethanol Placebo P
Parameter (n =226) (n =222)
Strictly endoluminal CRBSI 2 7 .10
Presumed endoluminal CRBSI 8 9 .81
Combined primary endpoint 10 16 .23
Primary bacteremia 91 91 .95
Positive culture of catheter huba 8 11 .67
Positive culture of catheter tipb 49 57 .52
Exoluminal CRBSI 11 8 .64
Data represent numbers of events. CRBSI, catheter-related bloodstream
infection.
aPositive catheter hub cultures, performed during episodes of bacteremia
(n = 73 for ethanol; n = 74 for placebo).
bPositive results of overall catheter tip culture (n = 171 for ethanol; n = 176 for
placebo).
doi:10.1371/journal.pone.0010840.t002
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isms.[30] For microorganisms in established biofilms, which is the
case in CVCs, concentrations of 40% to 70% were required to
achieve a bactericidal effect because penetration into a biofilm is
harder to establish.[31] As a concern, it has been reported that a
100%-ethanol lock solution was associated with catheter occlu-
sion.[32] Another report showed that infusion of polyurethane
catheters with 70%-ethanol resulted in qualitative softening of the
catheters.[33] More recently, however, no changes were observed
on the biomechanical properties of polyurethane catheters, which
were submerged in an ethanol solution for 9 weeks.[34] An
overview of all recent studies, discussing the most relevant aspects
of the ethanol lock technique was published recently.[35]
Several factors may explain the lack of efficacy as observed in
our study. First, for practical reasons we used a lock time of 15
minutes daily per catheter lumen. This was decided because a
longer dwell time would have interfered too much with patient
care. A recent in vitro study showed that a significant 3-log
reduction in the number of biofilm-associated gram-positive cocci
occurred already after 20 minutes exposure to a 60%-ethanol lock
solution. A dwell time of 30 minutes was required for complete
eradication.[36] However, another in vitro study showed recently
that an exposure time of 1 minute to a 70%-ethanol solution was
sufficient for the sterilization of a bacterial biofilm.[37]
Second, a lock-based intervention will reasonably prevent only
endoluminal CRBSI. By employing strict definitions we tried to
differentiate endoluminal CRBSI from other entities. However,
the true sensitivity of hub cultures to detect endoluminal infection
is unknown. Furthermore, the incidence of strictly endoluminal
CRBSI in the placebo arm was as low as 0.032% (7 of 222
patients). Therefore, the study was underpowered in retrospect.
Taking this incidence rate into account, it can be calculated that
future studies in comparable patient populations should include
848 patients to demonstrate a 75% reduction with 80% power,
which is even augmented to 2282 patients to be able to show a
50% reduction of strictly endoluminal CRBSI.
Finally, bacteremia with CNS is not always CVC-related, but
may result from translocation from the bowel in patients with severe
mucositis.[38,39] This could explain why despite the high overall
incidence of CNS bacteremia, which occurred in 106 of all 182
episodes of bacteremia, no reduction of CNS bacteremia was seen
due to the use of ethanol locks. The use of antimicrobial prophylaxis
resulting in selective eradication of intestinal gram-negative but not
gram-positive microorganisms may be the underlying cause. To test
this hypothesis, we did genotypic identification of CNS in a random
sample of 15 patients with documented bacteremia who were found
to have concomitant CNS in rectal and/or vaginal mucosa or
mouth swabs. Identical CNS strains in blood and mucosa were
identified in 6 of 15 patients (40%).
Although the relevance of mucositis-associated bacteremia is not
fully elucidated yet, it may be hypothesized that an intervention
with an endoluminal CVC lock will not result in a reduction of
overall bacteremia in patients who are treated with high-dose
Table 3. Overview of cultured microbes in case of bacteremia
(182 episodes).
Ethanol Placebo
(n =91) (n =91)
CNSa,b 49 57
Other skin colonizers 2 2
Staphylococcus aureus 2 3
Other gram-positive cocci 12 10
Gram-negatives 4 5
Polymicrobial 20 13
Yeasts 2 1
Data represent numbers of episodes of bacteremia. CNS, coagulase-negative
staphylococci.
aOf all 106 episodes with CNS-bacteremia for which glycopeptide-therapy was
started, 32 were due to CRBSI (including endoluminal and exoluminal
infection). Of the remaining 74 episodes, tentative sources were mucositis
(n = 21), cytarabin skin toxicity (n = 8), contaminated blood cultures (n = 8), red
catheter insertion site without other criteria for exoluminal CRBSI (n = 6),
unknown (n = 29), and other causes (n = 2).
doi:10.1371/journal.pone.0010840.t003
Table 4. Tolerability and safety of study compound.
Ethanol Placebo P
Total cohort (n = 226) (n = 222)
All-cause mortality 7 5 .77
Thrombosis of insertion blood vessel 9 12 .62
Discontinuation of study compound 10 0 .002*
Modified lock frequency 11 1 .006*
Complete cessation 2 9 .50
Other eventsa
Questionnaireb (n = 88) (n = 93)
Subjective parameters
Facial flushing 39 17 ,.001*
Nausea/vomiting 20 17 .58
Altered taste 31 19 .04*
Feelings of dizziness/drowsiness 41 10 ,.001*
Data represent numbers of events; *denotes statistical significance.
aOne patient had syncope right after flushing the first lock solution into the circulation, 1 device had to be removed because of a rupture of a catheter lumen which
occurred during sleep.
bThe predefined analysis of subjective adverse effects was performed on a random sample of the total cohort by means of a questionnaire.
doi:10.1371/journal.pone.0010840.t004
Ethanol Lock against CRBSI
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10840
chemotherapy, and nearly inevitably suffer from severe mucositis.
Also, the observed rate of exoluminal compared to endoluminal
CRBSI in our study was higher than expected. Both these aspects
may explain why our initial hypothesis that the rate of CNS
bacteremia as observed in other studies reflects mainly endoluminal
CRBSI may have been inaccurate in retrospect. In this view, the
observed 3.6-fold reduction of strictly endoluminal CRBSI in
patients allocated to ethanol locks is reassuring, as is the 41%-
reduction of endoluminal CRBSI as expressed per 1000 CVC-
days, because the lack of statistical significance may reflect a lack
of power more than a lack of effectiveness.
However, the overall incidence of endoluminal CRBSI in our
patients was low. One wonders whether the clinical benefits of this
intervention, even in case of a significant reduction of endoluminal
CRBSI, in this specific patient population would outweigh the
extra amount of effort, costs and patient discomfort. Additional
studies should therefore be performed in populations with higher
incidence of (endoluminal) CRBSI, e.g., patients receiving long-
term treatment with TPN.
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